Shire confirms talks with Barr to resolve Adderall XR patent dispute

08/19/2005 | Times (London) (subscription required), The

Shire Pharmaceuticals confirmed reports it met with Barr Laboratories to resolve a dispute over its patent for Adderall XR, for attention deficit disorder. Shire is defending the patent against a challenge by Barr, which wants to produce a generic version of Adderall XR, but Shire said it was looking at options for settling the issue, including continuing a court fight to defend the patent.

View Full Article in:

Times (London) (subscription required), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park